Measles, mumps, and rubella virus vaccine (M-M-R™II): A review of 32 years of clinical and postmarketing experience

Vaccine

Volumn 30, Issue 48, 2012, Pages 6918-6926

  Lievano, Fabio ^a   Galea, Susan A ^a   Thornton, Michele ^a   Wiedmann, Richard T ^a   Manoff, Susan B ^a   Tran, Trung N ^a   Amin, Manisha A ^a   Seminack, Margaret M ^a   Vagie, Kristen A ^a   Dana, Adrian ^a   Plotkin, Stanley A ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Measles; Mumps; Rubella; Safety; Vaccine

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVERSE OUTCOME; ANAPHYLAXIS; ARTHRITIS; ARTICLE; ASEPTIC MENINGITIS; ATAXIA; AUTISM; BRAIN DISEASE; BRAIN HYPOXIA; BRONCHIOLITIS; COLD; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DYSPNEA; EAR INFECTION; ECZEMA; ENCEPHALITIS; ERYTHROPHAGOCYTOSIS; FAINTNESS; FEBRILE CONVULSION; FEVER; GUILLAIN BARRE SYNDROME; HEALTH CARE SURVEY; HEARING IMPAIRMENT; HUMAN; IMMUNE DEFICIENCY; INFECTION CONTROL; INJECTION SITE REACTION; LYMPHOCYTE COUNT; LYMPHOHISTOCYTOSIS; MEASLES; MEASLES VACCINATION; MEDICAL INFORMATION; MORBIDITY; MORTALITY; MUMPS; OPTIC NEURITIS; OTITIS MEDIA; PHARYNGITIS; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT INFECTION; RUBELLA; SIDE EFFECT; SUBACUTE SCLEROSING PANENCEPHALITIS; SUDDEN INFANT DEATH SYNDROME; THROMBOCYTOPENIA; TONSILLITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URTICARIA; WOLF HIRSCHHORN SYNDROME;

DRUG TOXICITY; HUMANS; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS; PRODUCT SURVEILLANCE, POSTMARKETING; RUBELLA;

EID: 84868202262     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.057     Document Type: Article

References (65)

1. Plotkin S.A. Rubella vaccine. Vaccines 1999, W.B. Saunders Company, Philadelphia (PA), pp. 409-39. 3rd ed. S.A. Plotkin, W.A. Orenstein (Eds.).
2. Centers for Disease Control and Prevention (CDC) Summary of notifiable diseases-United States, 1993. Morb Mortal Wkly Rep 1994, 42:1-73.
3. Centers for Disease Control and Prevention (CDC) Summary of notifiable diseases-United States 2009. Morb Mortal Wkly Rep 2011, 58:1-100.
4. Centers for Disease Control and Prevention (CDC) Notifiable diseases and mortality tables. Morb Mortal Wkly Rep 2011, 60:1362-1375.
5. Centers for Disease Control and Prevention (CDC) Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 1998, 47:1-57.
6. Centers for Disease Control and Prevention (CDC) Achievements in Public Health: elimination of rubella and congenital rubella Syndrome-United States, 1969-2004. Morb Mortal Wkly Rep 2005, 54:279-282.
7. Barskey A., Glasser J.W., LeBaron C.W. Mumps resurgence in the United States: a historical perspective on unexpected elements. Vaccine 2009, 27:6186-6195.
8. Plotkin S.A., Farquhar J., Katz M., Ingalls T.H. A new attenuated rubella virus grown in human fibroblasts: evidence for reduced nasopharyngeal excretion. Am J Epidemiol 1967, 86:468-477.
9. Plotkin S.A., Cornfeld D., Ingalls T.H. Studies of immunization with living rubella virus: trials in children with a strain cultured from and aborted fetus. Am J Dis Child 1965, 110:381-389.
10. Plotkin S.A., Farquhar J.D., Ogra P.L. Immunologic properties of RA27/3 rubella virus vaccine: a comparison with strains presently licensed in the United States. JAMA 1973, 225:585-590.
11. Plotkin S.A., Farquhar J.D., Katz M., Buser F. Attenuation of RA 27/3 rubella virus with WI-38 human diploid cells. Am J Dis Child 1969, 118:178-185.
12. Parker Fiebelkorn A., Redd S.B., Gallagher K., Rota P.A., Rota J., Bellini W., et al. Measles in the US during the postelimination era. J Infect Dis 2010, 202:1520-1528.
13. Roush S.W., Murphy T.V., Vaccine-Preventable Disease Table Working Group Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007, 298:2155-2163.
14. Centers for Disease Control and Prevention (CDC) Global measles mortality, 2000-2008. Morb Mortal Wkly Rep 2009, 58:1321-1326.
15. EUVAC.net. Measles surveillance annual report. 2010. Available at: [accessed 26.10.11]. http://www.euvac.net/graphics/euvac/pdf/annual_2010.pdf.
16. Peltola H., Jokinen S., Paunio M., Hovi T., Davidkin I. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect Dis 2008, 8:796-803.
17. European Medicines Agency. M-M-RVAXPRO. Available at: [accessed 19.06.12]. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/000604/human_med_000907.jsp%26murl=menus/medicines/medicines.jsp%26jsenabled=true.
18. Wiese-Posselt M., Tertilt C., Zepp F. Vaccination recommendations for Germany. Dtsch Arztebl Int 2011, 108:771-780.
19. Hilleman M.R., Buynak E.B., Weibel R.E., Stokes J., Whitman J.E., Leagus M.B. Development and evaluation of the Moraten measles virus vaccine. JAMA 1968, 206:587-590.
20. Weibel R.E., Stokes J., Buynak E.B., Whitman J.E., Hilleman M.R. Live, attenuated mumps virus vaccine - clinical and serologic aspects in a field evaluation. N Engl J Med 1976, 276:245-251.
21. Hilleman M.R., Weibel R.E., Buynak E.B., Stokes J., Whitman J.E. Live, attenuated mumps virus vaccine - protective efficacy as measured in a field evaluation. N Engl J Med 1967, 276:252-258.
22. Cutts F.T., Henderson R.H., Clements C.J., Chen R.T., Patriarca P.A. Principles of measles control. Bull WHO 1991, 69:1-7.
23. Leibhaber H., Ingalls T.H., LeBouvier G.L., Hortsmann D.M. Vaccination with RA 27/3 rubella vaccine. Am J Dis Child 1972, 123:133-136.
24. Centers for Disease Control and Prevention (CDC) Current Trends Mumps-United States, 1980-1983. Morb Mortal Wkly Rep 1983, 32:545-547.
25. Brown G.C., O'Leary T.P. Fluorescent-antibody marker for vaccine-induced rubella antibodies. Infect Immun 1970, 2:360-363.
26. Buynak E.B., Hilleman M.R. Live attenuated mumps virus vaccine. 1. Vaccine development. Proc Soc Exp Biol Med 1966, 123:768-775.
27. Weibel R.E., Carlson A.J., Villarejos V.M., Buynak E.B., McLean A.A., Hilleman M.R. Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. Proc Soc Exp Biol Med 1980, 165:323-326.
28. Centers for Disease Control and Prevention (CDC) Progress towards measles elimination-European Region 2005-2008. Morb Mortal Wkly Rep 2009, 58:142-145.
29. Centers for Disease Control and Prevention (CDC) Measles elimination-United States, January-May, 2011. Morb Mortal Wkly Rep 2011, 60:666-668.
30. Aronson S.M. Mumps, branks and other impediments. Med Health R I 2006, 89:297.
31. Centers for Disease Control and Prevention (CDC) Update: mumps outbreak - New York and New Jersey, June 2009-January 2010. Morb Mortal Wkly Rep 2010, 59:125-129.
32. Savage E., Ramsay M., White J., Beard S., Lawson H., Hunjan R., et al. Mumps outbreaks across England and Wales in 2004: observational study. BMJ 2005, 330:1119-1120.
33. Reef S.E., Frey T.K., Theall K., Abernathy E., Burnett C.L., Icenogle J., et al. The changing epidemiology of rubella in the 1990: on the verge of elimination and new challenges for control and prevention. JAMA 2002, 287:464-472.
34. Centers for Disease Control and Prevention (CDC) Progress toward control of rubella and prevention of congential rubella syndrome-worldwide 2009. Morb Mortal Wkly Rep 2010, 59:1307-1310.
35. Strebel P.M., Gacic-Dobo M., Reef S., Cochi Global use of rubella vaccines, 1980-2009. J Infect Dis 2011, 204:s579-s584.
36. Zimmerman L.A., Muscat M., Janovic D., Goel A., Bang H., Khetsuriani N., et al. Status of rubella and congenital rubella syndrome surveillance, 2005-2009, the World Health Organization European Region. J Infect Dis 2011, 204:s381-s388.
37. Vaccine Adverse Event Reporting System. Available at: [accessed 19.06.12]. http://vaers.hhs.gov/index.
38. Institute of Medicine, National Research Council 4 Measles, mumps, and rubella vaccine. Adverse effects of vaccines: evidence and causality 2012, The National Academies Press, Washington, DC, Available at http://www.iom.edu/Reports/2011/Adverse-Effects-of-Vaccines-Evidence-and-Causality.aspx [accessed 19.06.12].
39. U.S. Food and drug Administration. MedWatch. The FDA Safety Information and Adverse Event Reporting Program. Available at: [accessed 19.06.12]. http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm.
40. Monafo W.J., Haslam D.B., Roberts R.L., Zaki S.R., Bellini W.J., Coffin C.M. Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. J Pediatr 1994, 124:273-276.
41. Bitnun A., Shannon P., Durward A., Rota P.A., Bellini W.J., Graham C., et al. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 1999, 29:855-861.
42. Weitzman S., Manson D., Wilson G., Allen U. Fever and respiratory distress in an 8-year old boy receiving therapy for acute lymphoblastic leukemia. J Pediatr 2003, 142:714-721.
43. Angel J.B., Walpita P., Lerch R.A., Sidhu M.S., Masurekar M., DeLellis R.A., et al. Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med 1998, 129:104-106.
44. Xu S., Zhang L., Nelson Zeng C., Mullooly J., McClure D., et al. Identifying optimal risk windows for self-controlled case series studies of vaccine safety. Statist Med 2011, 30:742-752.
45. National Institutes of Health. DMID Pediatric Toxicity Tables, November 2007. Available at: [accessed 21.06.12]. http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/Documents/dmidpedtox.pdf.
46. Nojd J., Tecle T., Samuelsson A., Orvel C. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype. Vaccine 2001, 19:1727-1731.
47. Centers for Disease Control and Prevention (CDC) Brief Report. Imported case of congenital rubella syndrome-New Hampshire 2005. Morb Mortal Wkly Rep 2005, 54:1160-1161.
48. M-M-R®II [package insert]. Whitehouse Station, NJ: Merck & Co., Inc. 2010. Available at: [accessed 26.10.11]. http://www.merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf.
49. Centers for Disease Control and Prevention (CDC) General Recommendations on Immunization Recommendations of the Advisory Committee on Immunization Practices (ACIP) Recommendations and Reports. Morb Mortal Wkly Rep 2006, 55:1-48.
50. Pickering L.K., Baker C.J., Kimberlin D.W., Long SS Red Book: 2009 report of the committee on infectious diseases 2009, American Academy of Pediatrics, Elk Grove Village (IL). 28th ed.
51. Epidemiology and prevention of vaccine-preventable diseases 2011, Public Health Foundation, Waldorf, MD. 12th ed. W. Atkinson, S. Wolfe, J. Hamborsky (Eds.).
52. Sawaishi Y., Abe T., Yano T., Ishikawa K., Takada G. SSPE following neonatal measles infection. Pediatr Neurol 1999, 20:63-65.
53. Sharp G.B., Laney S.M., Westmoreland B.F., Groover R.V. Atypical electroencephalographic pattern in a patient with subacute sclerosing panencephalitis. Electroencephalogr Clin Neurophysiol 1991, 78:311-313.
54. Eroglu E., Gokcil Z., Bek S., Ulas U.H., Ozdag M.F., Odabasi Z. Long-term follow-up of patients with adult-onset subacute sclerosing panencephalitis. J Neurol Sci 2008, 275:113-116.
55. Tapiainen T., Prevots R., Izurieta H.S., Abramson J., Bilynsky R., Bonhoeffer J., et al. Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine 2007, 25:5793-5802.
56. Institute of Medicine (US) Immunization Safety Review Committee Immunization safety review: vaccines and autism 2004, National Academies Press, Washington, DC.
57. Adverse effects of vaccines: evidence and causality 2011, National Academy Press, Washington, DC. K. Stratton, A. Ford, E. Rusch, E.W. Clayton (Eds.).
58. Vestergaard M., Hviid A., Madsen K.M., Wohlfahrt J., Thorsen P., Schendel D., et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA 2004, 292:351-357.
59. Consolini D.M. Thrombocytopenia in infants and children. Pediatr Rev 2011, 32(4):135-151.
60. Centers for Disease Control and Prevention (CDC) Notes from the field: measles outbreak-Indiana, June-July 2011. Morb Mortal Wkly Rep 2011, 60:1169.
61. Dayan G.H., Quinlisk M.P., Parker A.A., Barskey A.E., Harris M.L., Schwartz J.M., et al. Recent resurgence of mumps in the United States. N Engl J Med 2008, 358:1580-1589.
62. Hartnell N.R., Wilson J.P. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004, 24:743-749.
63. Manners P.J., Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much?. J Rheumatol 2002, 29:1520-1530.
64. Tingle A.J., Allen M., Petty R.E., Kettyls G.D., Chantler J.K. Rubella-associated arthritis. Comparative study of joint manifestations associated with natural rubella infection and RA27/3 rubella immunization. Ann Rheum Dis 1986, 45:110-114.
65. Centers for Disease Control and Prevention (CDC). Vaccines: Pubs/Guidelines for Vaccinating Pregnant Women. Available at: [accessed 19.06.12]. http://cdc.go/vaccines/pubs/preg-guide.htm.